632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial

Integrated machine learning, cosmic signatures, and AI-driven genomic profiling of highly heterogeneous blast crisis CML at single patient level resolution: Implication as a versatile risk stratification and precision oncology approach

Two decades of pregnancy outcomes in women with CML Insights from a real world single center cohort

Changes in disease responses after discontinution of tyrosine kinase inhibitors TKI for pregnancy in established chronic myeloid leukaemia CML Evidence for the basis of advice for women of child bearing age

Updated efficacy and safety of olverembatinib HQP1351 as second line therapy in patients pts with chronic Phase chronic myeloid leukemia CP CML

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia Interim results from the restop Trial

Exploring co mutations in CML and ph b ALL with ABL1 variants Correlations with survival and treatment response

Asciminib ASC in chronic myeloid leukemia in chronic Phase CML CP Interim analysis IA efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed 1L patients pts

Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors A retrospective US population level analysis

Preliminary safety and efficacy of ELVN 001 a selective active site inhibitor of BCR ABL1 in patients with CML driven by atypical fusion transcripts

Whole genome sequencing reveals that the Philadelphia chromosome Ph can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor TKI resistance